Please sign in to follow a disease.
Kaposi's sarcoma
MONDO:0005055A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).
Also known as: KS, Kaposi sarcoma, Kaposi's sarcoma, Kaposi's sarcoma (disease), Kaposi's sarcoma of anus, Kaposi's sarcoma of central nervous system, Kaposi's sarcoma of esophagus, Kaposi's sarcoma of gastrointestinal sites
2871 clinical trials for this condition and its sub-types, 45 tagged with Kaposi's sarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Kaposi's sarcoma
-
Classic Kaposi sarcoma 3 trials
-
Endemic Kaposi sarcoma 1 trial
-
Iatrogenic Kaposi's sarcoma 1 trial
-
Colorectal Kaposi sarcoma 0 trials
2 sub-types
- Colon Kaposi sarcoma 0 trials
- Rectum Kaposi sarcoma 0 trials
-
New drug cocktail shows promise for rare HIV-Linked cancer
Disease control OngoingThis early-phase trial tested whether combining two anti-cancer drugs, pomalidomide (taken as a pill) and liposomal doxorubicin (given through an IV), is safe and tolerable for people with advanced or hard-to-treat Kaposi sarcoma. The study enrolled 62 adults, including those wit…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug shows promise against rare skin cancer
Disease control OngoingThis phase II trial tests the drug pomalidomide in about 45 people with Kaposi sarcoma, a rare skin cancer. Pomalidomide works by stopping blood vessel growth and boosting the immune system to fight cancer cells. The study aims to see how long tumors shrink and how many people re…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Radioactive seeds zapped tumors from inside – early trial shows promise
Disease control OngoingThis study is testing a device called DaRT that delivers alpha radiation directly into tumors. It is for people with skin cancer, mouth tumors, or superficial soft tissue sarcoma who have not responded to other treatments or cannot have standard therapy. The goal is to see if the…
Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental drug shows promise for rare HIV-Linked cancer
Disease control OngoingThis early-stage study tests the safety of dostarlimab, an immunotherapy drug, in people with HIV-related Kaposi sarcoma that hasn't responded to standard HIV treatment. About 15-20 participants will receive the drug alongside their HIV therapy. The goal is to see if the drug is …
Phase 1 • Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Cancer combo drug trial for rare skin cancer withdrawn before starting
Disease control CancelledThis study planned to test a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare skin cancer called classic Kaposi sarcoma that had not responded to prior chemotherapy. The goal was to see if the combination could shrink tumors better than standard chemo…
Phase 2 • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Hidden bone loss: HIV and cancer patients under the scanner
Knowledge-focused OngoingThis study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
New study aims to personalize chemo for HIV-Linked cancer
Knowledge-focused OngoingThis study follows 127 people with HIV-related Kaposi sarcoma in Malawi and South Africa who are receiving standard chemotherapy (paclitaxel or bleomycin plus vincristine). Researchers want to understand why some patients respond better than others, looking at factors like gender…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC